MedMatrix Rx
Daily Briefing on 340B Policy and Litigation Developments
The 340B program landscape continues to shift as HRSA revives its rebate model pilot, prompting legislative and legal challenges. The SUSTAIN 340B Act, introduced by bipartisan senators, aims to reform the program, potentially ending HRSA’s rebate pilot. Meanwhile, pharmaceutical companies have filed lawsuits against state-level 340B regulations, intensifying the legal battles surrounding the program. These developments highlight the ongoing complexity and contentious nature of the 340B program.
EXECUTIVE SUMMARY
01
HRSA Revives 340B Rebate Model Pilot.
HRSA announced a revised 340B Rebate Model Pilot Program, requiring manufacturers to submit rebate plans by August 24, 2026.
HRSA announced a revised 340B Rebate Model Pilot Program, requiring manufacturers to submit rebate plans by August 24, 2026.
02
SUSTAIN 340B Act Introduced in Senate.
A bipartisan group of senators introduced the SUSTAIN 340B Act to reform the 340B program and potentially end HRSA’s rebate pilot.
A bipartisan group of senators introduced the SUSTAIN 340B Act to reform the 340B program and potentially end HRSA’s rebate pilot.
Source: AHA News
03
Pharmaceutical Companies Sue Illinois Over 340B Law.
AbbVie, Novartis, and Bristol Myers Squibb filed lawsuits against Illinois to block its new 340B contract pharmacy law.
AbbVie, Novartis, and Bristol Myers Squibb filed lawsuits against Illinois to block its new 340B contract pharmacy law.
Source: Endpoints News
04
Court Upholds HHS Control Over 340B Rebate Models.
The D.C. Circuit ruled that manufacturers cannot implement 340B rebate models without HHS approval.
The D.C. Circuit ruled that manufacturers cannot implement 340B rebate models without HHS approval.
Source: Becker’s Hospital Review
05
South Dakota Court Dismisses 340B Lawsuits.
A federal judge in South Dakota dismissed lawsuits challenging the state’s 340B contract pharmacy law.
A federal judge in South Dakota dismissed lawsuits challenging the state’s 340B contract pharmacy law.
Source: Becker’s Hospital Review
06
HRSA’s Revised 340B Pilot Faces Legislative Opposition.
A new Senate bill seeks to terminate HRSA’s 340B rebate pilot and establish a national data clearinghouse.
A new Senate bill seeks to terminate HRSA’s 340B rebate pilot and establish a national data clearinghouse.
Source: MedCity News
07
340B Reform Legislation Advances in Congress.
Congress is considering multiple 340B reform bills, including the SUSTAIN 340B Act, amid ongoing program challenges.
Congress is considering multiple 340B reform bills, including the SUSTAIN 340B Act, amid ongoing program challenges.
Source: Becker’s Hospital Review
08
D.C. Circuit’s Decision on 340B Rebates.
The D.C. Circuit confirmed that HHS must approve any 340B rebate models before implementation by manufacturers.
The D.C. Circuit confirmed that HHS must approve any 340B rebate models before implementation by manufacturers.
Source: The FDA Law Blog
09
Senate Bill Seeks to Codify 340B Program Rules.
The SUSTAIN 340B Act aims to provide statutory clarity for the 340B program, addressing contract pharmacies and rebate models.
The SUSTAIN 340B Act aims to provide statutory clarity for the 340B program, addressing contract pharmacies and rebate models.
Source: AJMC
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The introduction of the SUSTAIN 340B Act marks a significant legislative effort to reform the 340B program. If passed, this bill could reshape the program by codifying rules and potentially ending the HRSA rebate pilot. This legislative move reflects the ongoing tensions between federal agencies, lawmakers, and stakeholders in the healthcare industry. The outcome of this bill could have far-reaching implications for hospitals, manufacturers, and patients reliant on the 340B program.
Emerging risks.
- HRSA’s revised 340B rebate pilot may increase administrative burdens on hospitals.
- Legal challenges to state 340B laws could create uncertainty for contract pharmacies.
- Potential termination of HRSA’s rebate pilot could disrupt current rebate arrangements.
- Ongoing litigation may delay the implementation of new 340B program reforms.
Emerging opportunities.
- The SUSTAIN 340B Act could provide clarity and stability to the 340B program.
- A national data clearinghouse could improve transparency and compliance.
- Revised rebate models may offer manufacturers better claims visibility.
- Legislative reforms could strengthen program integrity and patient access.
Key actions for providers.
- Hospitals should prepare for potential changes in 340B program administration.
- Manufacturers must submit rebate plans to HRSA by August 24, 2026.
- Stakeholders should engage with policymakers on the implications of the SUSTAIN 340B Act.
- Monitor ongoing litigation for developments affecting 340B program operations.
TOP STORIES
HRSA Revives 340B Rebate Model Pilot.
The FDA Law Blog · August 9, 2026
- HRSA announced a revised 340B Rebate Model Pilot Program on August 3, 2026.
- The pilot requires manufacturers to provide 340B pricing through rebates for selected drugs.
- Eligible manufacturers must submit rebate plans by August 24, 2026.
- The pilot takes effect on January 1, 2027, for Medicare Drug Price Negotiation Program drugs.
SUSTAIN 340B Act Introduced in Senate.
AHA News · August 5, 2026
- The SUSTAIN 340B Act was introduced by a bipartisan group of senators.
- The bill aims to reform the 340B program and codify the use of contract pharmacies.
- It proposes terminating HRSA’s rebate pilot and establishing a national data clearinghouse.
- The legislation seeks to improve transparency, reporting, and program integrity.
Pharmaceutical Companies Sue Illinois Over 340B Law.
Endpoints News · August 11, 2026
- AbbVie, Novartis, and Bristol Myers Squibb filed lawsuits against Illinois.
- The lawsuits challenge the state’s new 340B contract pharmacy law.
- The legal actions reflect ongoing tensions between states and drug manufacturers.
- The outcome could influence similar laws in other states.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
HRSA’s 340B Rebate Pilot Faces Legislative Opposition.
MedCity News · August 7, 2026
- A Senate bill seeks to end HRSA’s 340B rebate pilot within a year.
- The bill proposes a national data clearinghouse to address duplicate discounts.
- Bipartisan senators argue the pilot burdens providers with administrative costs.
- The bill aims to improve transparency and compliance in the 340B program.
Congress Advances New Wave of 340B Legislation.
Becker’s Hospital Review · August 10, 2026
- Six senators introduced sweeping 340B reform legislation.
- The SUSTAIN 340B Act adds a Senate counterpart to a House bill.
- Congress has three active 340B proposals to consider.
- The legislation addresses contract pharmacies and rebate models.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| N.D. Ill. | AbbVie Inc. v. Raoul [source] | August 7, 2026 |
| N.D. Ill. | Berliner v. Huang [source] | July 31, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company [source] | July 27, 2026 |
| E.D. Mich. | Henry Ford Hospital v. CVS Health Corporation [source] | July 16, 2026 |
WHAT TO WATCH NEXT
- HRSA’s deadline for manufacturers to submit rebate plans is August 24, 2026. [source]
- Congressional consideration of the SUSTAIN 340B Act and other reform proposals. [source]
- Potential legal developments in the Illinois 340B lawsuits filed by AbbVie, Novartis, and Bristol Myers Squibb. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.